Infants typically weigh between two and five kilograms during their first months. In malaria-prone regions, this has long made treatment difficult. Health workers often split or dilute larger pills, increasing the chances of either underdosing or toxic effects. With this approval, that workaround may no longer be necessary.

The new formulation uses the same antimalarial agents already used for older age groups, but in smaller, carefully balanced doses. It dissolves in breast milk and has a cherry flavor, making it easier for caregivers to give and infants to swallow.

Why This Matters

In 2023, malaria claimed close to 600,000 lives, according to data from the World Health Organization. Nearly all of these deaths (around 95%) happened in Africa, with children under the age of five making up the majority of the fatalities. While malaria in newborns is less frequent than in toddlers, the lack of infant-specific medicine has left a gap in care.

Dr. Quique Bassat, director of the Barcelona Institute for Global Health, said newborn cases might be fewer, but they still require the same level of attention. “Even if numbers are lower, the need for safe and precise treatment remains,” he noted.

Babies are especially vulnerable because they cannot receive malaria vaccines until about five months of age. For infants born in malaria-endemic areas, that early window carries risk. WHO estimates suggest around 36 million pregnancies occurred in 33 African countries affected by malaria last year.

In about one-third of those cases, mothers contracted malaria during pregnancy, which raises the chance of passing the infection to their babies.

“Each baby born in these areas starts life already at risk,” said Dr. Lutz Hegemann, who oversees Novartis’ global health division.

What Comes Next

Swissmedic’s approval involved input from eight African countries, including Kenya, Nigeria, and Uganda. These countries participated in evaluating the drug through a regulatory partnership, allowing them to act quickly on final approval. Within the next 90 days, these nations are expected to authorize the treatment and begin distribution.

Novartis has stated that it intends to distribute the new infant malaria treatment on a mostly non-commercial basis. Still, health experts are urging the company to clarify what that means in practical terms.

She also warned that funding cuts and rising drug resistance continue to challenge malaria programs. Even as new tools like vaccines and mosquito control efforts expand, access remains uneven—particularly in places affected by conflict or climate-related disruptions.

A Better Fit for a Difficult Problem

The Swiss approval used a special fast-track process, reserved for treatments urgently needed in developing countries. It’s only the third time Swissmedic has used this method, which it operates in coordination with the WHO.

The move may also signal a shift in how regulators collaborate with low-resource countries. By involving local experts early in the evaluation, the system speeds up adoption without lowering safety standards.

In past years, treating newborns with malaria has been like trying to wrap a small parcel using sheets designed for furniture—too big, too imprecise, and requiring constant adjustment. With Coartem Baby, the fit becomes much more exact.

The medicine is based on familiar compounds but tuned for smaller bodies. By bringing the dose closer to the actual need, it reduces error and avoids the guesswork that once made newborn malaria treatment both risky and difficult.

[Source: 1,2]

The post Switzerland Approves First Malaria Drug for Newborns appeared first on Medical Journal Daily.

Naegleria fowleri, commonly referred to as the “brain-eating amoeba,” is typically found in soil and warm freshwater environments such as lakes, rivers, and hot springs. It can cause severe brain infections when contaminated water enters the body through the nose, according to the US Centers for Disease Control and Prevention (CDC).

The victim, a healthy 25-year-old man, likely encountered the amoeba while swimming at Gai Beach on the shores of the Kinneret in northern Israel. He was initially admitted to Sharon Hospital with symptoms of fever, headaches, and vomiting. As his condition worsened, he was transferred to Beilinson Hospital in Petah Tikvah for advanced treatment.

Despite exhaustive medical efforts, including drug treatments and surgical interventions, the man’s condition continued to decline, leading to his death. Beilinson Hospital stated, “From the moment he was hospitalized, medical teams used everything at their disposal to save the patient’s life, but his condition continued to deteriorate.”

While Naegleria fowleri thrives in warm water, most individuals who swim in these environments do not become infected. The Israeli Health Ministry dispatched environmental health inspectors to examine Gai Beach, but initial tests did not reveal any contamination.

The Health Ministry is continuing its investigation and will update the public as necessary.

Naegleria fowleri infections are extremely rare but almost always fatal. According to the CDC, only about 400 cases have been recorded worldwide. Symptoms typically appear within one to nine days of exposure and include headaches, fever, nausea, vomiting, and a stiff neck, progressing to neurological symptoms such as confusion, seizures, and hallucinations. Immediate medical attention is crucial for anyone showing signs of infection.

Additional Information and Preventive Measures

Naegleria fowleri infections are often associated with activities in warm freshwater during the summer months. The amoeba enters the brain through the nasal passages, making it crucial to avoid getting water up the nose. Preventive measures recommended by health authorities include:

1. Avoiding Water Activities in Warm Freshwater: Particularly in areas with reported cases of Naegleria fowleri.
2. Using Nose Clips: When engaging in water-related activities in warm freshwater.
3. Avoiding Disturbing Sediment: In shallow, warm freshwater areas where the amoeba might reside.

Research and awareness are vital to prevent such infections. The CDC provides comprehensive guidelines and updates on Naegleria fowleri, emphasizing the importance of public education in reducing the risk of exposure.

Sources:

1. Centers for Disease Control and Prevention (CDC).
   “Naegleria fowleri – Primary Amebic Meningoencephalitis (PAM).” CDC Website
2. World Health Organization (WHO).
   “Naegleria Infection.” WHO Website
3. Beilinson Hospital.
   Official Statement on Patient’s Condition and Treatment Efforts.
4. The Times of Israel.
   “Man Dies After Contracting Brain-Eating Amoeba in Israel’s 2nd Ever Recorded Case.” The Times of Israel

The post Tragic Death of Israeli Man from Rare Brain-Eating Amoeba appeared first on Medical Journal Daily.